Low expression of Ki-67/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status
Journal of Neuro-Oncology · 2023-06 · 163 (2) · 339-344
DOI: 10.1007/s11060-023-04342-2 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Neuro-Oncology, online erschienen am 25.05.2023. Verfasst von Paolo Tini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Radiotherapy, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy. paolo.tini@unisi.it. Hauptthemen laut MEDLINE: Glioblastoma, Glioma, Brain Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Siena.
Abstract (Originalsprache)
Purpose
The Ki-67/MIB-1 labeling index (LI) is clinically used to differentiate between high and low-grade gliomas, while its prognostic value remains questionable. Glioblastoma (GBM) expressing wild-type isocitrate dehydrogenase IDH wt , a relatively common malignant brain tumor in adults, is characterized by a dismal prognosis. Herein, we have retrospectively investigated the prognostic role of Ki-67/MIB-1-LI in a large group of IDH wt GBM.
Methods
One hundred nineteen IDH wt GBM patients treated with surgery followed by Stupp’s protocol in our Institution between January 2016 and December 2021 were selected. A cut-off value for Ki-67/MIB-1-LI was used with minimal p-value based approach.
Results
A multivariate analysis showed that Ki-67/MIB-1-LI expression < 15% significantly correlated with a longer overall survival (OS), independently from the age of the patients, Karnofsky performance status scale, extent of surgery and O 6 -methylguanine (O6-MeG)-DNA methyltransferase promoter methylation status.
Conclusions
Among other studies focused on Ki-67/MIB-1-LI, this is the first observational study showing a positive correlation between OS of IDH wt GBM patients and Ki-67/MIB-1-LI that we propose as a new predictive marker in this subtype of GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Radiotherapy, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy. paolo.tini@unisi.it.
- Unit of Radiotherapy, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
- Unit of Diagnostic Imaging, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
- Unit of Pathological Anatomy, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
- Center for Biotechnology, College of Science and Technology, Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, USA.
- Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University, Rome, Italy.
Förderung
- Università degli Studi di Siena
Zitieren
APA
Tini, P., Yavoroska, M., Mazzei, M. A., Miracco, C., Pirtoli, L., Tomaciello, M., Marampon, F., & Minniti, G. (2023). Low expression of Ki-67/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status. Journal of Neuro-Oncology, 163(2), 339-344. https://doi.org/10.1007/s11060-023-04342-2
Vancouver
Tini P, Yavoroska M, Mazzei MA, Miracco C, Pirtoli L, Tomaciello M, et al. Low expression of Ki-67/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status. Journal of Neuro-Oncology. 2023;163(2):339-344. doi:10.1007/s11060-023-04342-2
BibTeX
@article{Tini2023,
author = {Tini, Paolo and Yavoroska, Mariya and Mazzei, Maria Antonietta and Miracco, Clelia and Pirtoli, Luigi and Tomaciello, Miriam and Marampon, Francesco and Minniti, Giuseppe},
title = {Low expression of Ki-67/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status},
journal = {Journal of Neuro-Oncology},
year = {2023},
volume = {163},
number = {2},
pages = {339--344},
doi = {10.1007/s11060-023-04342-2}
}
EUVIMED